Table 1 Baseline characteristics.

From: The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy

Number of patients (n)

31

Median age, years (median, range)

64 (31–77)

Male/female (n, %)

22 (71.0)/9 (29.0)

ECOG PS 0/1 (n, %)

13 (41.9)/18 (58.1)

Primary tumor location (n, %)

 Esophagogastric junction

6 (19.4)

 Upper

3 (9.7)

 Middle

11(35.5)

 Lower

10 (32.3)

 Unknown

1 (3.2)

 No. of metastatic site (median, range)

2 (1–4)

Metastatic site (n, %)

 Liver

15 (48.4)

 Lung

4 (12.9)

 Lymph node

20 (64.5)

 Peritoneum

13 (41.9)

Histology (n, %)

 Differentiated

10 (32.3)

 Undifferentiated

18 (58.1)

 Unknown

3 (9.7)

HER2 status (n, %)

 Positive

4 (12.9)

 Negative

27 (8.7)

EBER-ISH (n, %)

 Positive

3 (9.7)

 Negative

27 (12.9)

 NA

1 (3.2)

MMR status (n, %)

 dMMR

3 (9.7)

 pMMR

27 (8.7)

 NA

1 (3.2)

PD-L1 CPS (n, %)

 ≥ 5

8 (25.8)

 > 5, ≥ 1

5 (16.1)

 1 >

16 (51.6)

 NA

2 (6.5)

 No. of previous regimen (median, range)

3 (2–7)

  1. dMMR mismatch repair-deficient, EBER-ISH Epstein–Barr virus (EBV)-encoded RNA in-situ hybridization, ECOG PS Eastern Cooperative Oncology Group performance status, HER2 human epidermal growth factor receptor 2, MMR mismatch repair, NA not available, PD-L1 CPS programmed death ligand 1 combined positive score, pMMR mismatch repair-proficient.
Back to article page